The European Medicines Agency (EMA) announced on Friday 16 September, following the meeting of its Committee for Medicinal Products for Human Use (CHMP) (12-15 September), that it recommended converting the conditional marketing authorisations granted to the Covid-19 messenger RNA vaccines Comirnaty, developed by Pfizer andBioNTech, and Spikevax, developed by Moderna, into a standard marketing authorisation. This decision is taken during the second annual renewal procedure of this...